Type Condition

High Point, NC

207 Clinical Paid Trials near High Point, NC

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Ruxolitinib + Chemotherapy for Ovarian Cancer

Winston-Salem, North Carolina
This phase I/II trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin and to see how well they work in treating patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate together with paclitaxel and carboplatin may be a better treatment for epithelial ovarian, fallopian tube, or primary peritoneal cancer compared to paclitaxel and carboplatin alone.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Sex:Female

147 Participants Needed

Pomalidomide + Dexamethasone +/- Ixazomib for Multiple Myeloma

Winston-Salem, North Carolina
This randomized phase I/II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to see how well pomalidomide and dexamethasone with or without ixazomib works in treating patients with multiple myeloma that has come back. Biological therapies, such as pomalidomide and dexamethasone, may stimulate the immune system in different ways and stop cancer cells from growing. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether pomalidomide and dexamethasone are more effective with or without ixazomib in treating multiple myeloma.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

118 Participants Needed

Pemetrexed + Cisplatin +/- Cediranib for Mesothelioma

Winston-Salem, North Carolina
This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural mesothelioma. Drugs used in chemotherapy, pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving pemetrexed disodium and cisplatin together with cediranib maleate may kill more tumor cells.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

117 Participants Needed

Vorinostat + Rituximab + Chemotherapy for Diffuse Large B-Cell Lymphoma

Winston-Salem, North Carolina
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab and combination chemotherapy and to see how well it works in treating patients with newly diagnosed stage II, stage III, or stage IV diffuse large B-cell lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cell-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving vorinostat together with rituximab and combination chemotherapy may kill more cancer cells.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

83 Participants Needed

Triple Immune Regimen for HIV

Greensboro, North Carolina
The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

45 Participants Needed

AZD7760 for Chronic Kidney Failure

Winston-Salem, North Carolina
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 55

231 Participants Needed

Peposertib + Radiation Therapy for Pancreatic Cancer

Winston-Salem, North Carolina
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving M3814 and hypofractionated radiation therapy together may be safe, tolerable and/or more effective than radiation therapy alone in treating patients with locally advanced pancreatic cancer.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

98 Participants Needed

INO-5401 + INO-9012 + Atezolizumab for Bladder Cancer

Winston-Salem, North Carolina
This is a Phase I/IIA, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of INO-5401 + INO-9012 delivered by intramuscular (IM) injection followed by electroporation (EP), in combination with atezolizumab in participants with locally advanced unresectable or metastatic/recurrent Urothelial Carcinoma (UCa). The trial population is divided into two cohorts: Cohort A: Participants with locally advanced unresectable or metastatic/recurrent UCa, who have confirmed disease progression during or following treatment with anti-Programmed Death receptor-1/Programmed Death receptor Ligand-1 (anti-PD-1/PD-L1) therapy; Cohort B: Participants with locally advanced unresectable or metastatic/recurrent UCa, who are treatment naïve and ineligible for cisplatin-based chemotherapy. A safety run-in will be performed with up to six participants (safety analysis participants) from cohort A.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

35 Participants Needed

CLN-619 for Multiple Myeloma

Winston-Salem, North Carolina
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

30 Participants Needed

SNDX-5613 + Chemotherapy for Acute Myeloid Leukemia

Winston-Salem, North Carolina
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

76 Participants Needed

SGN-EGFRd2 for Advanced Cancer

Winston-Salem, North Carolina
This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much PF-08046052/SGN-EGFRd2 should be given to participants. Part C will use the dose found in parts A and B to find out how safe PF-08046052/SGN-EGFRd2 is and if it works to treat solid tumor cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

290 Participants Needed

Low-Nicotine Cigarettes for Heart Health

Winston-Salem, North Carolina
This trial is studying the effects of cigarettes with very low nicotine on smokers' hearts. It includes both daily and occasional smokers. Researchers will compare heart rate and other heart functions when participants smoke low-nicotine and regular cigarettes to see how reducing nicotine impacts heart health.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:21+

49 Participants Needed

Biologic Implant for Vaginal Aplasia

Winston-Salem, North Carolina
In this Phase 1, single site, clinical trial, Vulvar/vaginal Smooth muscle cells (SMC) and Epithelial Cells (EPC) are isolated from autologous patient's biopsy
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:15 - 45
Sex:Female

10 Participants Needed

Topical Acne Medications for Acne

Winston-Salem, North Carolina
Acne is a chronic condition that typically requires the use of multiple medications.1 Medication adherence is especially challenging for patients with chronic diseases and often decreases over time, especially for those using topical medications.1 Nonadherence can result in multiple negative effects including treatment failure, increased healthcare costs, and decreased quality of life. Primary nonadherence refers to problems acquiring and starting treatment. Challenges to this form of nonadherence include a lack of knowledge, misunderstanding of usage, poor communication with provider, increased cost, and fear of side effects.2 Secondary nonadherence refers to when the patient does not use the medication as prescribed. Hurdles to secondary nonadherence include delayed results, increased complexity of treatment plan, adverse effects, busy lifestyle, and inconvenience.2
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1

72 Participants Needed

Ketamine vs Midazolam for Tobacco Use Disorder

Winston-Salem, North Carolina
This trial tests how different drugs affect smoking habits and cravings in people who are not trying to quit. Participants receive an injection of either ketamine, midazolam, dexmedetomidine, or a saltwater solution. The study aims to see if these drugs can help reduce cravings and withdrawal symptoms.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:21 - 55

20 Participants Needed

Nebulized KB407 for Cystic Fibrosis

Winston-Salem, North Carolina
This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

12 Participants Needed

Azelaic Acid for Central Centrifugal Cicatricial Alopecia

Winston-Salem, North Carolina
This trial is testing azelaic acid to see if it can help people with Central Centrifugal Cicatricial Alopecia (CCCA), a challenging hair loss condition. Azelaic acid might reduce inflammation, which could help hair grow back. The study aims to determine the effectiveness of azelaic acid. Azelaic acid has been used effectively for treating acne and rosacea, and it has shown potential in promoting hair growth when combined with minoxidil.

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1
Sex:Female

15 Participants Needed

Pembrolizumab + Spine Radiosurgery for Spinal Tumors

Winston-Salem, North Carolina
The purpose of this research study is to find out what effects (good and bad) Pembrolizumab and radiosurgery have on participants with high-grade epidural disease of the spine.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1

10 Participants Needed

BI 1831169 + Ezabenlimab for Advanced Cancers

Winston-Salem, North Carolina
This trial is for adults with advanced cancers that can be injected and who have no other treatment options. It tests a new medicine, BI 1831169, alone and with another medicine, ezabenlimab, to see if they can help the immune system fight cancer. The study aims to find the highest safe doses and check if the medicines can shrink tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

190 Participants Needed

Aloe Vera Capsules for Interstitial Cystitis

Winston-Salem, North Carolina
This trial is testing whether strong, dried aloe vera capsules can help people with interstitial cystitis, a painful bladder condition. Aloe vera is known for its soothing effects and might reduce inflammation and pain. Participants will take increasing doses of the capsules over several months to see if their symptoms improve.

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1

100 Participants Needed

Why Other Patients Applied

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

Regenerative Medicine for COVID-19 Related ARDS

Winston-Salem, North Carolina
A Phase I, double- blinded, randomized, placebo- controlled study to test the safety of Lomecel-B in Adults suffering from mild to severe acute respiratory distress syndrome (ARDS) due to COVID-19 resultant from 2019-nCoV coronavirus infection, or resultant from influenza virus infection.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

70 Participants Needed

Salt Reduction Diet for High Blood Pressure

Winston-Salem, North Carolina
This trial is studying young adults who were born prematurely to understand how salt affects their blood pressure. Researchers will see if stopping the body from making uric acid can help lower their blood pressure and improve heart health. The goal is to find better ways to prevent and treat heart disease in this high-risk group. Uric acid has been suspected to be a risk factor for high blood pressure since the 1870s, and lowering uric acid has shown potential in reducing blood pressure in individuals with high blood pressure.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:22 - 33

120 Participants Needed

Bioengineered Penile Tissue for Penile Damage

Winston-Salem, North Carolina
The primary objective of this clinical trial is to evaluate the safety of autologous engineered corpora cavernosa + albuginea constructs for treatment of complex penile deformities. Autologous endothelial and smooth muscle cells obtained from enrolled subjects' corpora cavernosa biopsy sample, will be culture expanded in vitro and used to seed decellularized corpora cavernosa + albuginea obtained from cadaveric-donors to create autologous bioengineered corpora cavernosa/albuginea constructs for repair of damaged penile tissues.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18 - 60
Sex:Male

10 Participants Needed

Engineered Urethral Tissue for Urethral Stricture

Winston-Salem, North Carolina
This is a Phase I clinical study to determine the safety and efficacy of using autologous, engineered urethral constructs for the treatment of urethral strictures in adult males. The proposed study design is a prospective non-randomized and uncontrolled single-center investigation. Autologous urothelial cells (UCs) and smooth muscle cells (SMCs), obtained from enrolled male subjects' bladder tissue samples, will be culture expanded in vitro and used to seed tubular PGA scaffolds to create autologous urethral constructs for the repair of urethral strictures.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:21 - 75
Sex:Male

10 Participants Needed

Navtemadlin for Brain Cancer

Winston-Salem, North Carolina
This phase I trial studies the side effects and best dose of navtemadlin in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). Navtemadlin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

86 Participants Needed

T Lymphocyte Therapy for Lymphoma

Winston-Salem, North Carolina
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by binding those bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. Both antibodies and T cells have been used to treat patients with cancers. They both have shown promise, but neither alone has been sufficient to cure most patients. This study is designed to combine both T cells and antibodies to create a more effective treatment. The treatment that is being researched is called autologous T lymphocyte chimeric antigen receptor cells targeted against the CD30 antigen (ATLCAR.CD30) administration. In previous studies, it has been shown that a new gene can be put into T cells that will increase their ability to recognize and kill cancer cells. A gene is a unit of DNA. Genes make up the chemical structure carrying the patient's genetic information that may determine human characteristics (i.e., eye color, height and sex). The new gene that is put in the T cells in this study makes a piece of an antibody called anti-CD30. This antibody floats around in the blood and can detect and stick to cancer cells called lymphoma cells because they have a substance on the outside of the cells called CD30. Anti-CD30 antibodies have been used to treat people with lymphoma, but have not been strong enough to cure most patients. For this study, the anti-CD30 antibody has been changed so that instead of floating free in the blood part of it is now joined to the T cells. Only the part of the antibody that sticks to the lymphoma cells is attached to the T cells instead of the entire antibody. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric (combination) receptor-activated T cells seem to kill some of the tumor, but they do not last very long in the body and so their chances of fighting the cancer are unknown. The purpose of this research study is to determine a safe dose of the ATLCAR.CD30 cells that can be given to subjects after undergoing an autologous transplant. This is the first step in determining whether giving ATLCAR.CD30 cells to others with lymphoma in the future will help them. The researchers also want to find out what side effects patients will have after they receive the ATLCAR.CD30 cells post-transplant. This study will also look at other effects of ATLCAR.CD30 cells, including their effect on your cancer and how long they will survive in your body.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:3+

18 Participants Needed

Palovarotene for Liver Disease

Greensboro, North Carolina
The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy participants with normal liver function. The study will also assess the safety and tolerability of the single dose of palovarotene. Participants will be enrolled in stages and divided into three groups based on their liver function: * Group 1: Healthy participants with normal liver function * Group 2: Participants with moderate liver impairment * Group 3: Participants with severe liver impairment (only enrolled if Group 2 results are safe and acceptable) Blood samples will be taken to assess how the drug binds to proteins in the blood. Participants will undergo various safety checks and procedures. Participants will stay in the clinical unit until Day 5 for these assessments and will return on Day 10 for a final visit.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

32 Participants Needed

SGN-MesoC2 for Solid Tumors

Winston-Salem, North Carolina
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08052666/SGN-MesoC2. PF-08052666/SGN-MesoC2 is a type of antibody-drug conjugate (ADC). ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will have 3 parts. Part A and Part B of the study will find out how much PF-08052666/SGN-MesoC2 should be given to participants. Part C will use the information from Parts A and B to see if PF-08052666/SGN-MesoC2 is safe and if it works to treat solid tumor cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

365 Participants Needed

ABBV-383 for Multiple Myeloma

Winston-Salem, North Carolina
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety and pharmacokinetics of ABBV-383 in adult participants with relapsed/refractory (R/R) MM. ABBV-383 is an investigational drug being developed for the treatment of R/R MM. This study is broken into 3 Arms: Arm A with 2 parts and Arm B as an expansion. Participants will receive ABBV-383 as a subcutaneous (SC) injection and intravenous (IV) infusion in Arm A and SC injections of ABBV-383 in Arm B. Around 55 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 25 sites across the world In Arm A participants will receive one of two doses of ABBV-383 as an SC injection and (IV) infusions, during the 151 week study duration. In Arm B, participants will receive the selected dose from Arm A as SC injections, during the 151 week study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

55 Participants Needed

AMG 355 + Pembrolizumab for Advanced Solid Tumors

Winston-Salem, North Carolina
The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

535 Participants Needed

1234...7

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do clinical trials in High Point, NC pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in High Point, NC work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in High Point, NC 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in High Point, NC is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in High Point, NC several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in High Point, NC?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in High Point, NC?

Most recently, we added Peer Navigator Training for HIV Prevention in Hispanic/Latino Men, Checklist Bundle for Reducing Injury During Colonoscopy and Fat Cell Injection for Knee Osteoarthritis to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in North Carolina

Anxiety Clinical Trials in North Carolina

Schizophrenia Clinical Trials in North Carolina

ADHD Clinical Trials in North Carolina

Bipolar Disorder Clinical Trials in North Carolina

Multiple Sclerosis Clinical Trials in North Carolina

Autism Clinical Trials in North Carolina

Treatment Resistant Depression Clinical Trials in North Carolina

Borderline Personality Disorder Clinical Trials in North Carolina

Social Anxiety Disorder Clinical Trials in North Carolina

Parkinson's Disease Clinical Trials in North Carolina

Alzheimer's Disease Clinical Trials in North Carolina

By Location

Clinical Trials near Durham, NC

Clinical Trials near Charlotte, NC

Clinical Trials near Winston-Salem, NC

Clinical Trials near Chapel Hill, NC

Clinical Trials near Raleigh, NC

Clinical Trials near Asheville, NC

Clinical Trials near Greensboro, NC

Clinical Trials near Greenville, NC

Clinical Trials near Wilmington, NC

Clinical Trials near High Point, NC

Clinical Trials near Goldsboro, NC

Clinical Trials near Hickory, NC

Other People Viewed

By Subject

Top Treatment for Acupuncture Clinical Trials

102 Clinical Trials near Dayton, OH

Top Prostate Cancer Clinical Trials near Long Beach, CA

199 Clinical Trials near Fort Myers, FL

Top Achondroplasia Clinical Trials

Top Clinical Trials near Fleetwood, PA

137 Clinical Trials near Kalispell, MT

Top Lung Cancer Clinical Trials near Ventura, CA

Top Clinical Trials near Orange, CA

Top Clinical Trials near Grosse Pointe, MI

Top Clinical Trials near Hixson, TN

Top Schizophrenia Clinical Trials near Los Angeles, CA

By Trial

Hydrogen Rich Water for Brain Cancer

Dronabinol Effects on THC Metabolism During Pregnancy

TAK-981 + Pembrolizumab for Solid Cancers

Sertraline for Depression

PET Imaging for Pulmonary Arterial Hypertension

Brain Boost Program for Scleroderma

DystoniaNet Diagnosis for Dystonia

Binimetinib for Hairy Cell Leukemia

Smoke-Free Policy Support for Smoking Cessation

Multiple Therapies for Stage III Non-Small Cell Lung Cancer

Immunotherapy Combinations for Advanced Liver Cancer

Transcranial Magnetic Stimulation for Depression

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial